Motilal Oswal Keeps Zydus LifeSciences at Neutral What a Neutral Rating Actually Means for Investors

Motilal Oswal assigned a Neutral rating on Zydus LifeSciences with a target price of ₹1,080. Despite Zydus beating estimates on revenue, EBITDA and profit the brokerage sees limited upside from current levels. After three consecutive years of strong US growth in FY23-25, Zydus saw US sales decline 11% in Q4 FY26 in constant currency terms. The US is the most profitable market for Indian pharma companies any weakness here directly impacts future earnings potential and limits how much higher the stock can go. When a company earns in US dollars but reports in rupees, currency fluctuation can distort numbers. Constant currency removes the impact of exchange rate changes to show the true business performance. A 11% CC decline means US business actually shrunk regardless of rupee-dollar movement. Motilal Oswal raised earnings estimates by 5% for FY27 and 4% for FY28 a positive revision. But the stock is already trading close to their ₹1,080 target leaving minimal upside. At 21x forward earnings the valuation fairly reflects both the strengths and the US weakness. Track US segment recovery and limited competition product launches in FY27. Higher R&D spending and marketing investments signal Zydus is preparing for the next growth phase if US sales recover the rating could quickly upgrade to Buy. Motilal Oswal's Neutral call on $ZYDUSLIFE Zydus LifeSciences despite strong earnings beats teaches investors that brokerage ratings reflect future upside potential not just past performance, and that when a stock's price already reflects most of the good news a Neutral rating signals patience rather than action, making it essential to understand the difference between business quality and stock valuation before reacting to any brokerage recommendation. $SUNPHARMA $CIPLA $DRREDDY